Skip to content

Commentary: Psychedelic Psychiatry's Brave New World.

Bénédicte Nobile, Emilie Olié, Philippe Courtet

Frontiers in Psychiatry November 26, 2020 DOI: 10.3389/fpsyt.2020.594077 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Commentary Peer reviewed
Topics Psychedelic-assisted therapy
Keywords Mental health treatment Clinical integration Innovative psychiatry
Citations 2
Key points Argues that Nutt and colleagues' article on psychedelic psychiatry omitted the potential interest of psilocybin for preventing suicidal behavior (completed suicide and suicide attempts) and decreasing suicidal ideation, despite discussing its use for depression and addiction.

Abstract

In their recent article entitled “Psychedelic Psychiatry's Brave New World,” Nutt et al. (1) wrote that new research on psychedelic drugs, especially psilocybin, has highlighted their potential for psychiatric disorder management. In the past decade, many studies focused on psilocybin effects on mood disorders (2) showing that it can significantly improve depressive symptomatology for weeks and even for years in some people (1). However, Nutt et al. (1) focused on depression and addiction, without mentioning the potential interest of psilocybin to prevent suicidal behavior (SB; i. e. , completed suicide and suicide attempts) and to decrease suicidal ideation (SI).

Citations in the library

Explore topics